fashion -WSS

fashion

author：knowledge 2025-09-28 15:20:43 - browse：958

The cost of healthcare health technology assessment — APStock

Physicians are in line to absorb more Medicare cuts next year, while hospital outpatient departments and surgery centers will get billions in new revenue.

The base figure that determines how much physicians get paid by Medicare will decrease by 3.3% for 2024, the federal government said Thursday.

The cuts will not be distributed equally among all specialties. Indeed, primary care doctors, endocrinologists, nurse practitioners, and physician assistants would see their Medicare payment rates rise, on average, according to the annual payment rule. Cuts would be steepest for all types of radiologists, including interventionalists and nuclear medicine, as well as vascular surgeons.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： CRISPR base editing slashes cholesterol levels in monkeys

WSS

Pig kidney works a record two months in donated body

RSV injection headlines need to be accurate for good uptake

The biotech scorecard for Q4: 16 stock

PEPFAR is under serious threat — and so is global health

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

fashion

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Setback for rare diseases as Taysha Gene Therapies pulls back

Virginia high school admissions case could be legal follow

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Sports medicine is finally prioritizing gender equality

What to make of Biden’s latest efforts on cancer research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

PEPFAR is under serious threat — and so is global health

BioMarin wins approval for gene therapy to treat hemophilia A

2023 Nobel Prize in Medicine goes to Karikó and Weissman

hotspot

New weight loss drugs vying to be the next Wegovy or Mounjaro

What we owe ALS patients — and why one company fell short

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

New oral drug delivery patch is modeled after octopus tentacles

The Karikó problem: Lessons for funding basic research

What will Novo Nordisk's VC do with its influx of cash?

focus

hotspot

explore

explore